Total
0
Shares
ResApp Health (ASX:RAP) - CEO & Managing Director, Tony Keating
CEO & Managing Director, Tony Keating
Source: TechKnow
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ResApp Health (RAP) has secured a one-year, non-exclusive licencing agreement with AstraZeneca’s Japanese subsidiary
  • Under the agreement, ResApp will licence its cough counting technology to the COVID-19 vaccine producer for use in its smartphone app
  • The information gathered from this can then provide insight into the progression and management of respiratory disease
  • It’s the first time this particular technology will be used outside of a clinical trial environment after previously been used by AstraZeneca in a lung cancer trial
  • ResApp is up a solid 17.2 per cent on the market, trading at 6.8 cents per share

ResApp Health (RAP) has secured a one-year, non-exclusive licencing agreement with AstraZeneca’s Japanese subsidiary.

It marks ResApp’s second licencing arrangement with the pharmaceutical, which more recently garnered global attention for its COVID-19 vaccine production.

Under the arrangement, ResApp is set to licence its cough counting technology for
use in a program to support asthma patients. This will also be the first time the technology has been used outside of clinical trials.

It marks the company’s second licensing agreement with the AstraZeneca, which was secured in October last year which used the technology in a lung cancer clinical trial.

ResApp’s technology measures the frequency of patient coughs over extended periods of time, which then helps provide an insight into the progression and management of the respiratory disease.

More specifically, the cough counting tech will be included in AstraZeneca’s smartphone app, allowing patients to monitor their symptoms at home.

Broadly, ResApp describes the agreement as a significant validation from a leading global pharmaceutical.

The companies are set to work together to integrate the product into the smartphone app ensuring it meets the group’s specifications for use in the Japanese market.

AstraZeneca will pay an undisclosed annual licence fee to ResApp for each patient provided with AstraZeneca’s asthma management smartphone app.

ResApp is up a solid 17.2 per cent on the market, trading at 6.8 cents per share at 11:10 am AEDT.

RAP by the numbers
More From The Market Herald
APM (ASX:APM) - CEO, Michael Anghie

" APM Human Services (ASX:APM) expands, acquiring Lifecare

APM Human Services International (APM) has acquired physiotherapy and home care group Lifecare for $68 million.
Resonance Health (ASX:RHT)

" Resonance Health (ASX:RHT) submits LiverSmart to FDA

Resonance Health (RHT) has submitted its LiverSmart device to the Food and Drug Administration (FDA) for US regulatory clearance.
Dotz Nano (ASX:DTZ) - CEO, Gideon Shmuel

" Dotz Nano (ASX:DTZ) signs Malaysian distribution deal for COVID-19 tests

Dotz Nano (DTZ) has entered into a distribution agreement with ScienceVision to promote, sell and distribute its COVID-19 virus detection technology in Malaysia.
Kazia Therapeutics (ASX:KZA) - CEO, Dr James Garner

" Kazia Therapeutics (ASX:KZA) releases “positive” second-phase study results for brain cancer treatment

Kazia Therapeutics (KZA) has opened the trading day green after reporting positive final results from a second-phase clinical study of its paxalisib drug